_256_384.jpg)
The Indian companies that have been granted licences are Cipla, Sun Pharma, Laurus Labs, Divis Labs, Glenmark, Cadila, Torrent, Emcure, McLeods, SMS Pharmaceuticals, Strides, Biocon, Aurobindo Pharma, Hetero, Granules, Amneal, MSN, Arene Life Sciences and Viatris
Flattish volume growth and subdued new launches were key factors for last month
_256_384.jpg)
Ind-Ra expects IPM revenue growth of over 12% yoy for FY22.
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
Ind-Ra continues to expect IPM’s revenue to grow over 12% yoy in FY22
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
Post normalisation of high growth months of April and May this year the average IPM growth from June to August this year stood at 15.2 % YoY : Ind-Ra reports
Ind-Ra expects IPM revenue to grow over 12% YoY in FY22
The five pharma companies have entered into a collaboration agreement, wherein the parties will jointly sponsor, supervise and monitor the clinical trial in India
Subscribe To Our Newsletter & Stay Updated
